Pegylated erythropoietin - 3SBio

Drug Profile

Pegylated erythropoietin - 3SBio

Alternative Names: PEG EPO- 3SBio; Pegerythropoietin - 3SBio; RD 01

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sciprogen
  • Developer 3SBio
  • Class Antianaemics; Erythropoietins; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaemia

Most Recent Events

  • 08 Apr 2018 Phase-I clinical trials in Anaemia (In volunteers) in China (SC) (NCT03657238)
  • 22 Jan 2016 Preclinical trials in Anaemia in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top